Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 9/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954601 | 0.88 | KDM5A (0.38) | KDM5ANR3C2ALDH1A1MAPTTHRB | |
| SCHEMBL19954568 | 0.87 | IRAK4 (0.38) | KDM5ANR3C2ALDH1A1MAPTTHRB | |
| SCHEMBL19954626 | 0.85 | KDM4E (0.43) | KDM5AIDH1ALDH1A1MAPTTHRB | |
| SCHEMBL18163932 | 0.84 | KDM5A (0.43) | KDM5ANR3C2IDH1EPHX2LRRK2 | |
| SCHEMBL19954599 | 0.83 | NR3C2 (0.39) | NR3C2ALDH1A1MAPTTHRBHPGD | |
| SCHEMBL19954594 | 0.83 | GAA (0.46) | KDM5A | |
| SCHEMBL18161145 | 0.83 | KDM5A (0.52) | KDM5A | |
| SCHEMBL19954630 | 0.82 | NR3C2 (0.36) | KDM5ANR3C2ALDH1A1MAPTTHRB | |
| SCHEMBL19954569 | 0.82 | PKM (0.41) | NR3C2EPHX2ALDH1A1MAPTTHRB | |
| SCHEMBL19954655 | 0.81 | GAA (0.36) | NR3C2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | KDM5A 2043/4885NR3C2 4324/4885IDH1 641/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | KDM5A 2043/4885NR3C2 4324/4885IDH1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.